Palisade Bio's Participation in Major Healthcare Event
Palisade Bio, Inc. (Nasdaq: PALI), a forward-thinking company dedicated to developing next-generation oral PDE4 inhibitors, is gearing up for a significant event in the biopharmaceutical landscape. On a Thursday, their Chief Executive Officer, JD Finley, and Chief Medical Officer, Dr. Mitchell Jones, are set to engage in a live fireside chat at the Piper Sandler 37th Annual Healthcare Conference.
Details of the Fireside Chat
The presentation is scheduled for 10:30 AM ET, marking a pivotal moment for Palisade Bio as they share their innovative approaches to treating inflammatory and fibrotic diseases. The conference represents a vital platform for dialogue with potential investors and partners, and the Palisade team is eager to highlight their advances in clinical research.
Engagement Opportunities for Investors
Beyond the fireside chat, Palisade Bio will also host one-on-one meetings with qualified investors at the conference. This offers a unique opportunity for attendees to engage directly with company leadership and discuss the exciting potential of their drug development initiatives.
About Palisade Bio's Mission
Palisade Bio is on a mission to revolutionize treatment for patients suffering from chronic inflammatory and fibrotic conditions. Utilizing their distinct prodrug platform, they aspire to provide safer, more effective oral therapies that cater to the varying needs of these patient populations. Their lead program, PALI-2108, exemplifies this commitment.
Overview of PALI-2108
PALI-2108 is an innovative locally-bioactivated PDE4 inhibitor prodrug tailored for patients with moderate-to-severe Ulcerative Colitis and Fibrostenotic Crohn’s Disease. These diseases often leave patients with few options that are non-immunosuppressive, creating a pressing need for new treatments. Recent reports from a Phase 1b trial have shown promising results, with a 100% clinical response rate in the UC participant cohort, showcasing PALI-2108's safety profile, which includes no serious adverse events.
Looking Ahead: Future Studies and Trials
As they continue to move forward, Palisade Bio is preparing to embark on a Phase 2 clinical study focused on Ulcerative Colitis. This study aims to assess not only the clinical remission and response but also to analyze pharmacodynamic biomarkers over a 12-week period. The company also plans to extend its research efforts into Fibrostenotic Crohn’s Disease, working diligently to expand the understanding and therapeutic potential of PALI-2108 across inflammatory bowel disease indications.
Connecting with Palisade Bio
To learn more about their innovative approaches and the exciting developments on the horizon, interested parties are encouraged to visit their official website. Palisade Bio is committed to transparency and invites briefings regarding their ongoing projects and strategic goals.
Frequently Asked Questions
What is the focus of Palisade Bio's research?
Palisade Bio is committed to developing innovative oral therapies for inflammatory and fibrotic diseases through PDE4 inhibitor prodrugs.
When will the fireside chat take place?
The fireside chat is scheduled for Thursday at 10:30 AM ET during the Piper Sandler Conference.
What is the significance of PALI-2108?
PALI-2108 is Palisade Bio's leading program aimed at treating Ulcerative Colitis and Crohn's Disease, showing strong clinical response rates in trials.
Who can participate in the one-on-one meetings?
Qualified members of the investor community registered for the conference will have the opportunity to meet with Palisade Bio's management.
How can I get more information about Palisade Bio?
More information can be found on the official Palisade Bio website, where details of their investigations and initiatives are regularly updated.